期刊文献+

基于寡肽转运体的缬沙坦拟肽前药设计与合成

Design and synthesis of valsartan peptidomimetic prodrugs based on oligopeptide transporter
原文传递
导出
摘要 目的为了改善缬沙坦的口服生物利用度,基于寡肽转运体(oligopeptide transporter,Pep T)的转运特点,设计并合成基于寡肽转运体的缬沙坦拟肽系列前药。方法基于寡肽转运体底物模型和缬沙坦分子结构,设计12个缬沙坦拟肽前药;以Trt-缬沙坦和带保护基的氨基酸原料,经缩合、脱保护得到2个缬沙坦氨基酸酯;以带保护基的不同氨基酸为原料,缩合得系列二肽化合物,然后分别与Trt-缬沙坦经缩合、脱保护得到10个缬沙坦二肽酯。结果合成了12个基于寡肽转运体的缬沙坦拟肽前药,目标化合物与关键中间体的化学结构经1H-NMR、MS确证。结论基于Pep T的底物特征,设计并合成了12个缬沙坦拟肽前药,为该类前药的深入研究奠定基础。 Objective To study the design and synthesis of valsartan peptidomimetic prodrugs based on oligopeptide transporter(Pep T),with the aim of improving the intestinal absorption of valsartan.Methods Tw elve of valsartan peptidomimetic prodrugs were designed based on the molecular structure of valsartan and the substrate model of oligopeptide transporter.Valsartan amino acid esters were synthesized by condensation,followed by deprotection,then the intermediate condensed with Trt-valsartan,follow ed by deprotection to give valsartan dipeptide esters.Results Twelve valsartan peptidomimetic prodrugs were synthesized,and the chemical structures of targeting compounds and key intermediates were confirmed by 1H-NMR and MS spectra.Conclusions Twelve valsartan peptidomimetic prodrugs were designed and synthesized based on the characteristics of Pep T substrates,which might provide proof for the further investigation of the similar prodrugs.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2014年第12期955-961,共7页 Journal of Shenyang Pharmaceutical University
基金 吉林化工学院科技计划项目(201350)
关键词 寡肽转运体 缬沙坦 设计 合成 oligopeptide transporter valsartan design synthesis
  • 相关文献

参考文献13

  • 1BRODIN B, NIELSEN C U, STEFFANSEN B, et al. Transport of peptidomimetic drugs by the intestinal di/ tri-peptide transporter, PepT1 [J]. Pharmacol Toxicol, 2002,90 ( 6 ) : 285 - 296.
  • 2TERADA T, INUI K. Peptide transporters:structure, function, regulaion and application for drug delivery [J].Curr Drug Metab ,2004,5 (1) :85 -94.
  • 3KULKARNI A A, HAWORTH I S, UCHIYAMA T, et al. Analysis of transmembrane segment 7 of the dipeptide transporter hPepT1 by cysteine-scanning mu- tagenesis [J]. J Bio Chem, 2003,278 ( 51 ) : 51833 - 51840.
  • 4印志,操锋,平其能.PepT1靶向前药的研究进展[J].药学进展,2011,35(1):15-22. 被引量:2
  • 5BAILEY P D,BOYD C A,BRONK J R,et al. How to make drugs orally active:a substrate template for pep- tide transporter PepT1 [ J]. Angew Chem Int Ed Engl, 2000,39(3) :505 -508.
  • 6FLESCH G, MiiLLER P, LLOYD P. Absolute bio- availability and pharmacokinetics of valsartan, an an- giotensin II receptor antagonist, in man [ J ]. Eur J Clin Pharmacol, 1997,52 ( 2 ) : 115 - 120.
  • 7CALDWELL S T, COOKE G, FITZPATRICK B, et al. A flavin-based [ 2 ] catenane [ J ]. Chem Commun, 2008, (45) :5912 - 5914.
  • 8MELTZER P C, KRYATOVA O, PHAM-HUU D P,et al. The synthesis of bivalent 213-carbomethoxy-313- ( 3,4-dichlorophenyl) -8-heterobicycloE 3.2.1 ] octanes as probes for proximal binding sites on the dopamine and serotonin transporters [J]. Bioorg Med Chem, 2008,16(4) : 1832 - 1841.
  • 9KLECAN O, RADL S, STACH J. Method of remo- ving the triphenylmethane protecting group: US, 10569428[ P ]. 2004 - 08 - 26.
  • 10STELAKATOS G C, ARGYROPOULOS N. Amino- acid 4-methoxybenzyl esters[J].J Chem Soc C, 1970, (7) :964 -967.

二级参考文献32

  • 1Dobson P D, Kell D B. Carrler-mediated cellular uptake of pharmaceutical drugs : an exception or the rule [ J ]. Nat Rev Drug Discov,2008,7 ( 3 ) :205-220.
  • 2Terada T, Inui K. Peptide transporters : structure, function, regulation and application for drug delivery [ J ]. Curr Drug Metab ,2004,5 ( 1 ) :85-94.
  • 3Meredith D. The mammalian proton-coupled peptide cotransporter PepT1: sitting on the transporter-channel fence? [ J ]. Philos Trans R Soc Lond B Biol Sci, 2009, 364(1514) :203-207.
  • 4Dias C, Nashed Y, Atluri H, et al. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val- valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS[ J]. Curr Eye Res ,2002,25 (4) :243-252.
  • 5Atluri H,Anand B S,Patel J,et al. Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration[ J ]. Exp Eye Res, 2004,78 ( 4 ) : 815-822.
  • 6Lu H, Klaassen C. Tissue distribution and thyroid hormone regulation of PepT1 and Pept2 mRNA in rodents [ J ]. Peptides,2006,27 ( 4 ) :850-857.
  • 7Teuscher N S, Novotny A, Keep R F, et al. Functional evidence for presence of PepT2 in rat choroid plexus: studies with glycylsarcosine [ J ]. J Pharmacol Exp Ther , 2000,294 ( 2 ) : 494- 499.
  • 8Groneberg D A, Nickolaus M, Springer J, et al. Localiza- tion of the peptide transporter PepT2 in the lung: implica- tions for pulmonary oligopeptide uptake[ J]. Am J Pathol, 2001,158(2) :707-714.
  • 9Brandsch M. Transport of drugs by proton-coupled peptide transporters:pearls and pitfalls [ J ]. Expert Opin Drug Metab Toxicol,2009,5 ( 8 ) : 887-905.
  • 10Naruhashi Kazumasa, Sai Yoshimichi, Tamai Ikumi, et al. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil lon- gitudinally in the rat intestine [ J ]. Pharm Res, 2002, 19 (10) :1417-1423.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部